Tildacerfont + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome
Trial Timeline
May 15, 2022 → Aug 31, 2023
NCT ID
NCT05370521About Tildacerfont + Placebo
Tildacerfont + Placebo is a phase 2 stage product being developed by Spruce Biosciences for Polycystic Ovary Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT05370521. Target conditions include Polycystic Ovary Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05370521 | Phase 2 | Terminated |
Competing Products
20 competing products in Polycystic Ovary Syndrome